NCT06430658View on ClinicalTrials.gov

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Esophagus Cancer
Interventions
COMBINATION_PRODUCT

Tislelizumab (BGB-A317) with chemoradiotherapy

Different sequences and methods of treatment to convert surgery

Trial Locations (1)

100021

RECRUITING

Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER